$HOLX (Hologic Inc.)

$HOLX {{ '2016-07-28T10:21:59+0000' | timeago}} • Webcast

$HOLX raised its 2016 outlook based on its strong 3Q16 performance. The company now expects non-GAAP EPS of between $1.93 and a $1.94. "We're clearly exceeding our own expectations for a sustainable bottom line growth, and feel good about our future prospects in this regard as well," CEO Stephen MacMillan said in an analyst call.

$HOLX {{ '2017-06-20T15:15:28+0000' | timeago}} • Announcement

$HOLX has obtained FDA clearance to market the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system. The test will be commercially available in the 50 United States, US territories and Puerto Rico.

$HOLX {{ '2017-06-15T13:06:41+0000' | timeago}} • Announcement

$HOLX said that the FDA has granted an expanded clearance for Cynosure's body contouring product, SculpSure, to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen and love handles.

$HOLX {{ '2017-05-16T20:13:23+0000' | timeago}} • Announcement

$HOLX announced that Charles J. Dockendorff has been elected to the company's Board of Directors, effective immediately.  Mr. Dockendorff also was appointed to the Audit and Finance Committee.

$HOLX {{ '2017-05-10T21:41:36+0000' | timeago}} • Webcast

$HOLX feels positive about its global molecular business which is becoming its largest product franchise and is accretive to its growth rate. The company is optimistic about the direction of this business going forward.

$HOLX {{ '2017-05-10T21:18:47+0000' | timeago}} • Webcast

$HOLX said there was no pricing impact to gross margins. The company is pleased with its pricing across all divisions. The GM impact was due to the blood screening divestiture. The over-performance of the blood screening was at a fairly low margin which impacted $HOLX negatively. FX and product mix also impacted GM but this was not significant.

$HOLX {{ '2017-05-10T21:13:17+0000' | timeago}} • Webcast

$HOLX said the international Breast Health business grew at about mid-single digit rate while the overall international business grew at double-digit rate. In the US, there is a bit of uncertainty due to the state of healthcare reform but this has not affected big hospitals. $HOLX is seeing slower growth in the US which it believes will improve.

$HOLX {{ '2017-05-10T20:34:08+0000' | timeago}} • Announcement

In 2Q17, $HOLX posted US sales of $570.1MM, up 4.1%. International sales of $145.3MM decreased 0.1%, but increased 2.8% in constant currency, led by strong growth in molecular diagnostics, GYN Surgical and Breast Health. GYN Surgical revenue of $101.1MM increased 11.2%. Breast Health revenue totaled $280.5MM, up 1.7% versus 2Q16.

$HOLX {{ '2017-05-10T20:30:21+0000' | timeago}} • Announcement

$HOLX expects FY17 revenue to grow 7.7-8.7% to $3.05-3.08Bil and EPS to grow 110.3-113.8% to $2.44-2.48. For 3Q17, revenue is expected to grow 10.1-12.2% to $790-805MM. EPS is expected to be $0.22-0.24 in 3Q17.

$HOLX {{ '2017-05-10T20:24:05+0000' | timeago}} • Announcement

$HOLX reported an increase of 664.8% in 2Q17 earnings. Net income was $526.8MM or $1.84 per share compared to $68.9MM or $0.24 per share in 2Q16. Diluted EPS grew 666.7% in 2Q17. Revenue grew 3.2% to $715.4MM compared to last year.

$HOLX {{ '2017-03-22T13:16:01+0000' | timeago}} • Announcement

Medical device maker $HOLX has completed the acquisition of Cynosure, Inc. for $66 per share in cash. The tender offer by a $HOLX unit for all the outstanding shares of Cynosure Class A common stock expired on March 21, 2017.  Approx 70.6% of Cynosure's outstanding shares were validly tendered into and not validly withdrawn from the offer.

$HOLX {{ '2017-02-14T18:20:22+0000' | timeago}} • Announcement

$HOLX said its Aptima Zika Virus diagnostic assay is now CE marked in Europe for the detection and diagnosis of the virus in patients at risk of exposure to Zika or with signs and symptoms of the virus. This is a molecular diagnostic test that identifies presence of Zika RNA in human serum, plasma and urine specimens.

$HOLX {{ '2017-02-14T16:11:53+0000' | timeago}} • Announcement

$HOLX agreed to buy $CYNO. This deal, along with blood screening divestiture, continues $HOLX's transformation into a higher growth company. $HOLX sees that together, the transactions will enable it to accelerate pro-forma revenue growth by roughly 150 basis points, and increase non-GAAP EPS at a solid double-digit rate, over next several years.

$HOLX {{ '2017-02-14T16:09:40+0000' | timeago}} • Announcement

$HOLX agreed to buy $CYNO. The transaction is expected to be dilutive to GAAP EPS. On a non-GAAP basis, $HOLX sees deal to be immediately accretive, adding about $0.03-0.05 to non-GAAP EPS in the balance of FY17, adding about $0.13-0.15 in non-GAAP EPS in FY18, and becoming increasingly accretive in FY19 and beyond.

$HOLX {{ '2017-02-14T16:09:15+0000' | timeago}} • Announcement

$HOLX agreed to buy $CYNO. The transaction is expected to be fully funded with cash on hand, including proceeds from the recently completed blood screening divestiture. $HOLX expects the deal to provide a high-single-digit return on invested capital by year five, exceeding its cost of capital.

$HOLX {{ '2017-02-14T16:05:38+0000' | timeago}} • Announcement

$HOLX agreed to buy all outstanding shares of $CYNO for $66 per share in cash, which corresponds to equity value of about $1.65Bil and enterprise value of $1.44Bil net of cash. A subsidiary of $HOLX will begin a tender offer to buy any and all outstanding shares of CYNO. The tender offer is expected to be completed in late March or April of 2017.

$HOLX {{ '2017-02-01T21:56:56+0000' | timeago}} • Webcast

$HOLX generated operating cash flow of $169.6MM in 1Q17. The company spent $24.7MM on capital, leading to free cash flow of $144.9MM. The company closed out the quarter with $646MM in cash and $3.3Bil in total debt outstanding, resulting in $2.7Bil of net debt.

$HOLX {{ '2017-02-01T21:46:58+0000' | timeago}} • Announcement

$HOLX lowered its 2017 revenue outlook to $2.785-2.825Bil from $2.94-2.98Bil and its non-GAAP EPS guidance to $1.90-1.94 from $2.12-2.16. The company now expects 2017 GAAP EPS of $2.73-2.77. For 2Q17, $HOLX sees revenue of $675-685MM, EPS of $1.85-1.86 and non-GAAP EPS of $0.45-0.46.

$HOLX {{ '2017-02-01T21:41:59+0000' | timeago}} • Announcement

$HOLX reported a rise in 1Q17 earnings driven by higher revenue as well as favorable product mix. Net income rose to $86.5MM or $0.30 per share from $84.9MM or $0.29 per share last year. Revenue grew to $734.4MM from $695.2MM. Non-GAAP EPS increased to $0.52 from $0.46.

$HOLX {{ '2017-02-01T21:39:58+0000' | timeago}} • Webcast

$HOLX said its efforts to revitalize its research and development pipeline are beginning to bear fruit as new products contributed progressively more to growth during 1Q17. The company added that it generated growth internationally after four consecutive quarters of declines in fiscal 2016.

$HOLX {{ '2017-01-04T21:17:10+0000' | timeago}} • Announcement

$HOLX appointed Jan Verstreken as its Regional President for EMEA and Canada. Prior to joining the company, Verstreken served as President of APAC region for Teleflex.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, April 25 2017 - 9:00pm
LH (Laboratory Corp. of America Holdings)
Tuesday, April 25 2017 - 1:00pm
ISRG (Intuitive Surgical, Inc.)
Tuesday, April 18 2017 - 8:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, March 14 2017 - 9:00pm

AlphaGraphics you may like